论文部分内容阅读
目的:探讨生脉胶囊对慢性心力衰竭大鼠基质金属蛋白酶与金属蛋白酶组织抑制因子的影响。方法:将75只雌性大鼠随机分为假手术组、心衰模型组、生脉胶囊组、卡托普利组、生脉胶囊加卡托普利组,采用腹主动脉缩窄法造成大鼠慢性心力衰竭模型,治疗7周时进行心肌基质金属蛋白酶-3(MMP-3)和金属蛋白酶组织抑制因子-1(TIMP-1)的检测。结果:①心衰模型组心肌MMP-3的含量高于假手术组(P<0.05),生脉胶囊组、卡托普利组、生脉胶囊加卡托普利组MMP-3的含量均低于心衰模型组(P<0.05);②心衰模型组心肌TIMP-1的含量低于假手术组(P<0.05),生脉胶囊组、生脉胶囊加卡托普利组分别高于心衰模型组(P<0.05或P<0.01),且生脉胶囊加卡托普利组高于卡托普利组(P<0.05)。结论:生脉胶囊可降低慢性心衰大鼠心肌MMP-3的含量,提高心肌TIMP-1含量,抑制心肌胶原的过度降解,能阻止心腔的扩大,与减轻慢性心衰心室重构有关。
Objective: To investigate the effect of Shengmai Capsule on matrix metalloproteinase and tissue inhibitor of metalloproteinase in rats with chronic heart failure. METHODS: Seventy-five female rats were randomly divided into sham operation group, heart failure model group, Shengmai capsule group, captopril group, Shengmai Capsule plus captopril group, and abdominal aorta constriction method was used to create large rats. In rat chronic heart failure model, myocardial matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were detected at 7 weeks of treatment. Results: 1 The content of MMP-3 in the heart failure model group was higher than that in the sham operation group (P<0.05). The contents of MMP-3 in the Shengmai capsule group, captopril group, Shengmai capsules and captopril group were all significant. Lower than the heart failure model group (P <0.05); 2 myocardial TIMP-1 content in the heart failure model group was lower than the sham operation group (P <0.05), Shengmai capsule group, Shengmai capsule plus captopril group were high In the heart failure model group (P<0.05 or P<0.01), the Shengmai Capsule plus captopril group was higher than the captopril group (P<0.05). Conclusion: Shengmai capsule can reduce the content of MMP-3 in myocardium of rats with chronic heart failure, increase the content of myocardial TIMP-1, inhibit the excessive degradation of myocardial collagen, can prevent the expansion of heart chamber, and is associated with the reduction of chronic heart failure ventricular remodeling.